Literature DB >> 24133183

HIV treatment, preexposure prophylaxis, and drug resistance: reconciling conflicting predictions from mathematical models.

Justin T Okano1, Sally Blower.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24133183      PMCID： PMC3864391          DOI： 10.1093/infdis/jit544

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  9 in total

1.  Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.

Authors:  Robert J Smith; Justin T Okano; James S Kahn; Erin N Bodine; Sally Blower
Journal:  Science       Date:  2010-01-14       Impact factor: 47.728

Review 2.  Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review.

Authors:  Kathryn M Stadeli; Douglas D Richman
Journal:  Antivir Ther       Date:  2012-10-10

Review 3.  Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.

Authors:  Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

4.  HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

Authors:  Virginie Supervie; J Gerardo García-Lerma; Walid Heneine; Sally Blower
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

5.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

6.  Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.

Authors:  Ume L Abbas; Robert Glaubius; Anuj Mubayi; Gregory Hood; John W Mellors
Journal:  J Infect Dis       Date:  2013-04-09       Impact factor: 5.226

7.  Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.

Authors:  Vivek Jain; Teri Liegler; Eric Vittinghoff; Wendy Hartogensis; Peter Bacchetti; Lauren Poole; Lisa Loeb; Christopher D Pilcher; Robert M Grant; Steven G Deeks; Frederick M Hecht
Journal:  PLoS One       Date:  2010-12-10       Impact factor: 3.240

8.  Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance.

Authors:  Virginie Supervie; Meagan Barrett; James S Kahn; Godfrey Musuka; Themba Lebogang Moeti; Lesego Busang; Lesogo Busang; Sally Blower
Journal:  Sci Rep       Date:  2011-12-07       Impact factor: 4.379

9.  Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).

Authors:  Urvi M Parikh; Photini Kiepiela; Shayhana Ganesh; Kailazarid Gomez; Stephanie Horn; Krista Eskay; Cliff Kelly; Barbara Mensch; Pamina Gorbach; Lydia Soto-Torres; Gita Ramjee; John W Mellors
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240
  9 in total
  2 in total

1.  How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact.

Authors:  Dobromir T Dimitrov; Marie-Claude Boily; Timothy B Hallett; Jan Albert; Charles Boucher; John W Mellors; Deenan Pillay; David A M C van de Vijver
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

2.  How could preventive therapy affect the prevalence of drug resistance? Causes and consequences.

Authors:  Amber Kunkel; Caroline Colijn; Marc Lipsitch; Ted Cohen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-05       Impact factor: 6.237
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.